Table 3.

Histoclinical characteristic of subanalysis patients with eosinophilic gastritis and/or duodenitis who had repeat histologic evaluation at baseline and on dupilumab

Characteristics	Eosinophilic gastritis subanalysis patients at baseline (n = 4)	Eosinophilic gastritis subanalysis patients on dupilumab (n = 4)	Eosinophilic duodenitis subanalysis patients at baseline (n = 6)	Eosinophilic duodenitis subanalysis patients on dupilumab (n = 6)
Peak gastric eos/hpf, median (min–max, Q1–Q3)	80.5 (32–150, 45.5–111)	7.5 (0–28, 1.5–16.8)
Peak duodenal eos/hpf, median (min–max, Q1–Q3)			39 (30–50, 37.3–46.3)	16.5 (0–50, 8–38.5)
Histologic remission on dupilumab, n (%)		4 (100)		4 (66.7)
Symptoms, n (%)
Dysphagia	3 (75)	0 (0)	5 (83.3)	1 (16.7)
Abdominal pain	4 (100)	2 (50)	6 (100)	3 (50)
Bloating/gas	2 (50)	2 (50)	2 (33.3)	2 (33.3)
Diarrhea	3 (75)	3 (75)	3 (50)	2 (33.3)
Constipation	2 (50)	0 (0)	2 (33.3)	0 (0)
Nausea/vomiting	4 (100)	2 (50)	5 (83.3)	1 (16.7)
Heartburn	4 (100)	2 (50)	5 (83.3)	2 (33.3)
Asymptomatic	0 (0)	1 (25)	0 (0)	1 (16.7)